Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nesiritide: trials and tribulations.

Rohit R Arora1

  • 1Department of Medicine, The Chicago Medical School, Chicago, Illinois, USA. rohit.arora@va.gov

Journal of Cardiovascular Pharmacology and Therapeutics
|October 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Dioxin and Dioxin-like Congeners With Hypertension.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2019
Same author

Cryptogenic Stroke: To Close a Patent Foramen Ovale or Not to Close?

Journal of central nervous system disease·2018
Same author

The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.

Journal of cardiovascular pharmacology and therapeutics·2018
Same author

The Need for Extracorporeal Membrane Oxygenation in Adults Undergoing Congenital Heart Surgery: Impact and Trends of Utilization.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2017
Same author

Arrhythmias in Adults with Congenital Heart Disease: What Are Risk Factors for Specific Arrhythmias?

Pacing and clinical electrophysiology : PACE·2016
Same author

Dominant Versus Nondominant Hand Cardiopulmonary Resuscitation: Is There Really True Dominance?

American journal of therapeutics·2016
Same journal

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Comparative Effectiveness of Renin-Angiotensin System Inhibitors in Heart Failure With Nonreduced Ejection Fraction: A Multicenter Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Shared Genetic Liability Between Heart Failure and Myocardial Infarction Revealed by Genome-Wide Cross-Trait Analysis.

Journal of cardiovascular pharmacology and therapeutics·2026
See all related articles

Physicians should reevaluate nesiritide use for acute decompensated heart failure due to recent meta-analyses showing increased risks. Current choices balance benefits against limited data, awaiting further trials.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute decompensated heart failure (ADHF) is a significant health issue.
  • Standard ADHF therapy includes diuretics, vasodilators, and inotropic agents.
  • Nesiritide is the sole FDA-approved drug for ADHF, a recombinant human B-type natriuretic peptide.

Purpose of the Study:

  • To reevaluate the use of nesiritide in ADHF patients.
  • To consider recent meta-analyses findings regarding nesiritide.
  • To analyze risks and benefits of nesiritide therapy in light of new data.

Main Methods:

  • Review of existing literature on nesiritide in ADHF.
  • Analysis of recent meta-analyses data.
  • Consideration of underlying disease pathophysiology and new trial insights.

Related Experiment Videos

Main Results:

  • Recent meta-analyses indicate an elevated risk of worsening renal function with nesiritide.
  • These studies also suggest an increased 30-day mortality associated with nesiritide.
  • Existing data on nesiritide's risks and benefits are limited and imperfect.

Conclusions:

  • Physicians must carefully reconsider nesiritide's role in ADHF treatment.
  • Therapeutic decisions should prioritize symptomatic and hemodynamic improvement.
  • Nesiritide may still be considered for its approved indication pending further clinical trials.